The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
1982
year mood +0.19 · +0.00 to +0.50 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov +0.50 Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.00+0.00+0.00+0.00+0.10+0.10+0.10+0.30+0.30+0.41+0.50+0.50

After a grim recessionary start, Volcker's August pivot ignited a new bull market and October's FDA approval of Humulin, the first gene-spliced drug, turned healthcare sharply positive, validating my biotech bets.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 06, 2026
Top healthcare stories of 1982
Oct
FDA Approves First Biotech Drug, Humulin, for Diabetes Treatment upi.com →

The FDA has approved Humulin, the first genetically engineered human insulin developed by Eli Lilly, Genentech, and City of Hope, marking a milestone in biotechnology. The synthetic insulin, produced using recombinant DNA technology, offers a safer, scalable alternative to animal-derived insulins with reduced risk of allergic reactions. This approval paves the way for expanded biotech drug development and could shift market preference toward human-identical insulin therapies.